Literature DB >> 30471524

Effect of alpha-lipoic acid supplementation on lipid profile: A systematic review and meta-analysis of controlled clinical trials.

Seyed Mohammad Mousavi1, Sakineh Shab-Bidar2, Hamed Kord-Varkaneh2, Masoud Khorshidi2, Kurosh Djafarian3.   

Abstract

Several studies have shown the effect of alpha-lipoic acid (ALA) on lipid profile. However, findings remain controversial. This systematic review and meta-analysis was conducted to systematically summarize the available clinical trials that examined the effects ALA supplementation on the lipid profile of adults. A systematic search through PubMed and Scopus was done for studies published in English up to April 2017. Effect sizes were combined with fixed- or random-effects analysis, where appropriate. Between-study heterogeneity was evaluated by Cochran's Q test and I2. Eleven clinical trials with 452 adults (51.5% women, 48.5% men) were included in this meta-analysis. Combining effect sizes of 10 studies on serum triacylglycerol (TG) concentrations revealed a significant effect of ALA supplementation on serum TG compared with the placebo group (weighted mean difference [WMD], -29.185 mg/dL; 95% confidence interval [CI], -51.454 to -6.916; P = 0.010). We also found significant changes in serum total cholesterol and low-density lipoprotein (WMD, -10.683 mg/dL; 95% CI, -19.816 to -1.550; P = 0.022, WMD, -12.906 mg/dL; 95% CI, -22.133 to -3.679; P = 0.006, respectively). Significant changes were not observed in serum high-density lipoprotein (WMD, -0.092 mg/dL; 95% CI, -3.014 to 2.831; P = 0.025). Supplementation dosage and body mass index were potential sources of heterogeneity, in which those with body mass index >30 kg/m2 who received >600 mg/d ALA showed better improvements in lipid profile. Our findings showed that supplementation with ALA significantly decreased the serum concentrations of TG, total cholesterol, and low-density lipoprotein but did not affect serum levels of high-density lipoprotein in adults.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALA; Alpha-lipoic acid; Lipid profile; Meta-analysis; Supplementation

Mesh:

Substances:

Year:  2018        PMID: 30471524     DOI: 10.1016/j.nut.2018.08.004

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  5 in total

1.  Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials.

Authors:  Aliyu Tijani Jibril; Ahmad Jayedi; Sakineh Shab-Bidar
Journal:  Endocr Connect       Date:  2022-09-26       Impact factor: 3.221

2.  The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Nima Baziar; Ensieh Nasli-Esfahani; Kurosh Djafarian; Mostafa Qorbani; Mehdi Hedayati; Mahshid Abd Mishani; Zeinab Faghfoori; Najva Ahmaripour; Saeed Hosseini
Journal:  Oxid Med Cell Longev       Date:  2020-03-09       Impact factor: 6.543

3.  Antioxidant Effect of Alpha-Lipoic Acid in 6-Hydroxydopamine Unilateral Intrastriatal Injected Rats.

Authors:  Pavlina Andreeva-Gateva; Lubomir Traikov; Zafer Sabit; Dimitar Bakalov; Radka Tafradjiiska-Hadjiolova
Journal:  Antioxidants (Basel)       Date:  2020-02-01

4.  The Impact of Decaffeinated Green Tea Extract on Fat Oxidation, Body Composition and Cardio-Metabolic Health in Overweight, Recreationally Active Individuals.

Authors:  Justin D Roberts; Ashley G B Willmott; Liam Beasley; Mariette Boal; Rory Davies; Laurence Martin; Havovi Chichger; Lata Gautam; Juan Del Coso
Journal:  Nutrients       Date:  2021-02-26       Impact factor: 5.717

5.  Exploring the effectiveness of vitamin B12 complex and alpha-lipoic acid as a treatment for diabetes mellitus/neuropathy: a protocol for systematic review and meta-analysis of randomised controlled trials.

Authors:  Portia Keabetswe Lekhanya; Kabelo Mokgalaboni
Journal:  BMJ Open       Date:  2022-08-25       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.